4
Changes in Ownership
Dyne Therapeutics, Inc. Filed Acc 0001915598-26-000002
Chief Commercial Officer sold 145 shares at $18.33 ($2,658)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Friedl-Naderer Johanna Chief Commercial Officer | 2026-06-16 | Sale 10b5-1 | −145 | $18.33 | $2,658 | 154,208 | D: show line 1 in the form |
| Open-market sales · 145 sh · avg $18.33 · $2,658 | |||||||
Loading xslF345X06/ownership.xml…